Larocca, A
Bringhen, S
Petrucci, M T
Oliva, S
Falcone, A P
Caravita, T
Villani, O
Benevolo, G
Liberati, A M
Morabito, F
Montefusco, V
Passera, R
De Rosa, L
Omedé, P
Vincelli, I D
Spada, S
Carella, A M
Ponticelli, E
Derudas, D
Genuardi, M
Guglielmelli, T
Nozzoli, C
Aghemo, E
De Paoli, L
Conticello, C
Musolino, C
Offidani, M
Boccadoro, M
Sonneveld, P
Palumbo, A
Article History
Received: 4 November 2015
Revised: 19 January 2016
Accepted: 2 February 2016
First Online: 22 February 2016
Competing interests
: AL has received honoraria from Celgene and Jannsen-Cilag. SB has received honoraria from Celgene, Janssen-Cilag and served on the advisory committee for Mundipharma. MTP has received honoraria from Celgene, Janssen-Cilag, Mundipharma, Sanofi, Amgen and Bristol-Myers Squibb. TC has received honoraria from Celgene, J&J, Amgen and Bristol-Myers Squibb. TG has received research funding from Celgene. CN has received honoraria from Celgene, Janssen-Cilag and Mundipharma. MO has received honoraria from Janssen-Cilag. MB has received consultancy fees from and served on the scientific advisory board for Jannsen-Cilag, Sanofi, Amgen and Celgene. PS has received research support from Onyx, Janssen, Celgene, Millennium and served on the advisory board for Onyx, Janssen, Celgene and Millennium. AP has received consultancy fees, research funding and honoraria from Jannsen-Cilag.